Related Experiment Video
Updated: Dec 19, 2025

Using a 1064-nm Picosecond Neodymium-Doped Yttrium Aluminum Garnet Laser for Periorbital Hyperpigmentation
Published on: May 23, 2025
Periorbital myxedema treated with intralesional hyaluronidase
Aleksandra L Lindgren1, Sharleen Sidhu2, Kathleen M Welsh3
1University of Queensland - Ochsner School of Medicine, 1524 Jefferson Highway, New Orleans, LA, USA.
Purpose:
Periorbital myxedema is one the most challenging symptoms for patients with Graves' eye disease (GED). The treatment of this condition is complex and often unsatisfactory. This case demonstrates the use of intralesional hyaluronidase to treat cosmetically concerning periorbital myxedema.
Observations:
Follow up showed no clinically significant recurrence of myxedema over one year.
Conclusion:
Intralesional hyaluronidase represented an effective and safe treatment of periorbital myxedema in a patient with Graves' eye disease.
Related Concept Videos
Angle Closure Glaucoma: Treatment
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...

